Health Service Research Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17603
Optimizing Tobacco Treatment Delivery for People Living with HIV
To conduct a randomized clinical trial with PLWH who smoke (N=230) comparing smoking cessation outcomes consistent with the RFA including: biochemically verified 7-day point prevalence abstinence (PPA) rates, continuous abstinence (Weeks 9-12), and the number of 24-hour quit attempts at the end of study treatment (Week 12) between participants who receive TAU and PrOMOTE.
Study InformationSTUDY22933
A Stepped Wedge Cluster Randomized Trial Comparing a Navigation-Based Multilevel Intervention With Treatment as Usual to Improve Initiation of Timely Postoperative Radiation Therapy in Adults with Locally Advanced Head and Neck Squamous Cell Carcinoma (The ENDURE Trial)
Primary Objective: 1. To evaluate the effectiveness of ENDURE compared with TAU on the initiation of timely, guideline-adherent PORT among patients with LAHNSCC undergoing surgical therapy with a pathologic indication for PORT as measured by the proportion of patients who initiate PORT within 6 weeks of surgery. Secondary Objectives: 1. To evaluate the effectiveness of ENDURE compared with TAU on the timely initiation of PORT among patients with LAHNSCC undergoing surgical therapy with a pathologic indication for PORT as determined by (1) median time-to-PORT initiation following surgery and (2) treatment package time. 2. To assess the effectiveness of ENDURE compared with TAU on racial disparities in the timely initiation of PORT among Black and White patients with LAHNSCC undergoing surgical therapy with a pathologic indication for PORT as determined by (1) the proportion of patients who initiate PORT within 6 weeks of surgery; (2) median time-to-PORT initiation following surgery; and (3) treatment package time. 3. To evaluate the effect of ENDURE compared with TAU on resolving barriers to timely PORT. 4. To compare the effect of ENDURE compared with TAU on satisfaction with cancer care as determined by Patient Satisfaction with Cancer Care scores. 5. To examine the mechanism through which ENDURE reduces treatment delays compared with TAU as measured by key (1) processes of cancer care delivery and (2) health behavior constructs at the patient and team levels. 6. To characterize the implementation outcomes related to fidelity, adaptation, acceptability, appropriateness, and feasibility of ENDURE across diverse care delivery settings. Primary Endpoint: PORT delay, defined per National Comprehensive Cancer Network (NCCN) Guidelines as the initiation of PORT > 6 weeks (42 days) following definitive surgery for HNSCC. Select Secondary Endpoints: Time-to-PORT initiation, defined as the number of days from the date of definitive surgery for HNSCC to the date of initiation of PORT. Treatment package time, defined as the number of days from the date of definitive surgery for HNSCC to the date of PORT completion. Patient Satisfaction with Cancer Care score. Pre-surgical radiation consultation, defined as the attendance by the patient at a consultation with the treating radiation oncologist prior to surgery to discuss radiation therapy in the definitive or adjuvant setting. Pre-radiation therapy dental extractions, defined as the extraction of indicated carious/non-restorable teeth prior to or during definitive surgery. Time from surgery to PORT referral, defined as the time, in days, from the date of the definitive surgical procedure to the date the referral (or postoperative appointment) is placed to discuss adjuvant therapy with the treating radiation oncologist. Time from PORT referral to appointment, defined as the time, in days, from the date of the definitive surgical procedure to the date that the patient attends a postoperative appointment with radiation oncology.
Study InformationSTUDY23695
The Impact of Cannabis and Tobacco/Nicotine Product Co Use in Young Adults: Prospective Cessation Evaluation and Substitution
Aim 1: Substitutability and Nicotine Treatment Outcomes. Evaluate the impact of behavioral economically derived measures of substance substitutability on Week 12 end of treatment (EOT) nicotine abstinence. Hypothesis 1: Participants with greater substitutability patterns will have lower rates of 7-day point prevalence abstinence from nicotine at EOT compared to patterns indicating a complementary relationship. Aim 2: Cannabis Demand and Use During Nicotine Treatment. Determine if treatment-induced nicotine abstinence, reduction or withdrawal is (a) associated with co-occurring changes in cannabis demand and use and (b) if substitutability modifies this relationship. Hypothesis 2: Nicotine use/withdrawal and associated changes in cannabis use and demand will be moderated by time varying changes in substitutability. Aim 3: Nicotine and Cannabis Use Changes During Treatment. Assess the reciprocal prospective relationship between nicotine and cannabis use (including reduction and abstinence) during nicotine treatment. Hypothesis 3: Cross-lagged changes in nicotine and cannabis use during treatment will have a positive correlation; i.e., increased cannabis use in the prior week will be associated with increased current nicotine use.
Study InformationSTUDY25353
NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (Symon)
Test the effectiveness of automated telephone system management (ATSM) + telephone interpersonal counseling (TIPC) versus active control on patient level outcome of the summary toxicity index of 24 PRO-CTCAE symptoms that include depressive, anxiety, and other symptoms commonly experienced during oral anti-cancer treatment over weeks 1-12 (immediate effect) and 13-17 (sustained effect).
Study InformationSTUDY25400
Exploratory Analysis of Metastatic Gynecologic Cancer Patient Experiences of Symptom Management in a Diverse Southeastern Population
The purpose of this study is to explore how socioeconomic status, race, and clinical variables affect gynecologic cancer patients perceived experiences with symptom management. The goal of this analysis is to understand patients undergoing cancer directed therapy who are underrepresented in clinical trials experience with symptom management and symptom burden. Hypothesis: Demographic and socioeconomic data in patients undergoing treatment for metastatic gynecologic cancer will have unique perceived experiences regarding their symptom management. These experiences will change how patients interact with the healthcare system as indicated by direct clinical variables such as direct admissions to the hospital for symptom management and prescribing factors.
Study InformationSTUDY25488
Priorities, Preferences, and Tradeoffs Among Older Adults with Oropharyngeal Cancer
To characterize the impact of aging and multimorbidity on treatment priorities and preferences among patients with OPC.
Study InformationSTUDY25751
Implementation of a Pilot Program for Opportunistic Salpingectomy at the Time of Gastrointestinal Surgery at MUSC: An Evaluation of Patient and Provider Knowledge and Attitudes
Specific Aim 1.1: Characterize the baseline knowledge and attitudes regarding OS among GI surgeons at MUSC. Hypothesis 1.1: OS is not an intervention that is familiar to GI surgeons. We hypothesize that many surgeons have limited knowledge regarding both its benefits as an ovarian cancer risk reduction strategy and the technical aspects of the procedure. Specific Aim 1.2: Characterize the baseline knowledge and attitudes regarding OS among patients undergoing GI surgery at MUSC CHS. Hypothesis 1.2: OS is not an intervention that is familiar to patients undergoing GI surgery. We hypothesize that patients have limited knowledge regarding its benefits as an ovarian cancer risk reduction strategy and minimal risk profile.
Study InformationSTUDY25923
A Stepped-Wedge Randomized Trial Using Multi-Faceted Surgeon-Focused Education to Evaluate the Impact of a Decision Support Tool and VTE-related Pre-Discharge Education to Increase Adherence to Guideline-Concordant Extended Venous Thromboembolism Prophylaxis After Major Abdominopelvic Cancer Surgery.
Characterize barriers and facilitators to ePpx guideline adherence as perceived by stakeholders via key informant interviews with a diverse group of patients and surgeons at four hospitals within the MUSC Health system that routinely perform abdominopelvic cancer surgery. Conduct a stepped-wedge randomized trial including multi-faceted surgeon-focused education and academic detailing to evaluate the impact of an EMR-based CDSS to increase adherence to ePpx guidelines at the three selected hospitals.
Study InformationSTUDY26220
Varenicline for e-cigarette cessation
The primary objective is to test the efficacy of varenicline vs. placebo for e-cigarette cessation in adults who report current e-cigarette use. Secondary objectives include examining predictors of e-cigarette cessation and potential moderators of varenicline response and exploring the effects of cessation on cancer-related health biomarkers.
Study InformationSTUDY26301
Engaging pharmacists to advance tobacco treatment service delivery for people living with HIV
To evaluate the effects of ENHANCE-TTS on pharmacists tobacco treatment care delivery adoption in 6 Ryan White HIV care settings. To evaluate implementation outcomes (acceptability, feasibility, fidelity, implementation cost, and penetration) across Ryan White clinics. To evaluate the effects of ENHANCE-TTS on patient-level tobacco treatment outcomes among PLWH.
Study Information